FDA Extends Review for Agios Sickle Cell Drug
The regulatory agency set a new February 2027 decision deadline for the supplemental application of mitapivat.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize safety during the drug approval process?
The FDA has extended its review period for the Agios supplemental New Drug Application (sNDA) regarding mitapivat for sickle cell disease. A new PDUFA goal date of February 1, 2027, has been set following a major amendment to the filing.
Why it matters
The extension follows an FDA request for additional information to determine if a Risk Evaluation and Mitigation Strategy (REMS) is necessary for the treatment. This review is part of the ongoing assessment of mitapivat under an accelerated approval pathway.
The sNDA submission includes nine months of updated safety data from the RISE UP Phase 2 and Phase 3 clinical trials. The Phase 3 study encompasses a cohort of 207 participants being evaluated for efficacy and safety.
The players
Agios
This is a biopharmaceutical company headquartered in Cambridge, Massachusetts, that focuses on developing medicines for rare diseases.
FDA
The Food and Drug Administration is the United States federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.
The details
Agios submitted a response to an FDA information request on October 19, 2026, which the regulator subsequently classified as a major amendment. The company is simultaneously advancing the REIGNITE Phase 3 confirmatory clinical trial, which began dosing patients in July 2026.
Timeline
July 2026: Agios dosed the first patient in the REIGNITE clinical trial.
October 9, 2026: The FDA requested additional information regarding a potential REMS.
October 19, 2026: Agios submitted a response to the FDA information request.
October 28, 2026: The FDA classified the company response as a major amendment.
February 1, 2027: This is the newly established PDUFA goal date for the sNDA.
The Tech Race
The application for mitapivat utilizes the FDA accelerated approval pathway to potentially bring new treatment options to market faster. This development reflects a broader industry trend of leveraging specific regulatory routes to address high-need conditions like sickle cell disease.
The delay postpones a potential decision on a new therapeutic option for individuals living with sickle cell disease. Patients and healthcare providers must now wait until February 2027 to see if the FDA approves the medication for clinical use.
The takeaway
Patients awaiting new treatments should note that regulatory timelines are subject to adjustments based on the review of safety data. Continuous engagement between pharmaceutical companies and regulators remains a standard feature of the drug approval process.
Further reading
For more information on clinical advancements in the sector, visit the Biotech section.
Live Poll
Do you trust that pharmaceutical companies prioritize safety during the drug approval process?
